AstraZeneca had a disappointing trial readout with its AKT inhibitor Truqap in breast cancer in June, so unsurprisingly it is trumpeting a first-in-class win for the drug in prostate cancer.

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca's Truqap (capivasertib) plus Faslodex (fulvestrant) for a specific type of breast cancer. The approval is for ...

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

The above results are likely to provide relief to investors after a combination therapy involving Truqap missed a late-stage study goal in certain breast cancer patients. Earlier in June ...

Nonetheless, we think growth momentum in other products will more than offset these, especially oncology drugs such as Imfinzi, Tagrisso, Calquence, Truqap, and Enhertu. The company gave a brief ...